
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is a promising investment opportunity due to its strong partnership with Regeneron Pharmaceuticals, which provides external validation of its capabilities, and its robust financial performance, with revenues of $230MM in 1Q26, ahead of expected estimates. Additionally, Telix's multiple clinical inflection points and advancements in its pipeline, including enrollment in pivotal studies and potential data readouts in the near future, make it a strong player in the radiopharmaceutical market.
Bears say
Telix Pharmaceuticals is a company that has seen success in their current revenue streams from the sales of Illuccix in the US, but their future potential for growth is dependent on the success of their pipeline of radiopharmaceutical drugs. While their partnership with Regeneron provides non-dilutive capital and potential long term upside, there is a significant risk of clinical and regulatory failures that could impact their future sales estimates and ultimately their stock price. Their current valuation and risks suggest that there is limited potential for growth, resulting in a negative outlook for the stock.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares